​

Voyager Therapeutics (VYGR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VYGR Stock Forecast

Voyager Therapeutics (VYGR) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $18.00 and a low of $10.00. This represents a 343.04% increase from the last price of $3.16.

- $4 $8 $12 $16 $20 High: $18 Avg: $14 Low: $10 Last Closed Price: $3.16

VYGR Stock Rating

Voyager Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (89.47%), 2 Hold (10.53%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 2 17 Strong Sell Sell Hold Buy Strong Buy

VYGR Price Target Upside V Benchmarks

TypeNameUpside
StockVoyager Therapeutics343.04%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$10.00$13.50
Last Closing Price$3.16$3.16$3.16
Upside/Downside-216.46%327.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25111---12
Mar, 25110---11
Feb, 25110---11
Jan, 25110---11
Dec, 2419---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 12, 2025Yanan ZhuWells Fargo$10.00$3.81162.47%216.46%
Nov 13, 2024Jay OlsonOppenheimer$18.00$6.92160.12%469.62%
Sep 25, 2024Jack AllenRobert W. Baird$18.00$6.04198.01%469.62%
May 14, 2024Laura ChicoWedbush$8.00$8.48-5.66%153.16%
Jan 02, 2024Jim BirchenoughWells Fargo$14.00$9.0055.56%343.04%
May 10, 2023Joon LeeTruist Financial$18.00$9.8882.19%469.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2025Wells FargoOverweightOverweighthold
Dec 02, 2024CitigroupBuyinitialise
Nov 13, 2024OppenheimerOutperformOutperformhold
Oct 16, 2024WedbushBuyBuyhold
Jul 31, 2024WedbushBuyBuyhold
May 14, 2024WedbushNeutralNeutralhold
May 10, 2023UBSBuyinitialise

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.99$-1.75$-1.21$3.08$-1.13----
Avg Forecast$0.85$-2.34$-1.16$1.44$-0.92$-1.60$-1.34$-1.31$-0.68
High Forecast$1.35$-0.96$-0.17$1.50$-0.67$-0.64$-0.55$-0.77$0.16
Low Forecast$0.35$-3.73$-1.96$1.35$-1.07$-3.11$-2.20$-2.05$-1.42
Surprise %16.47%-25.21%4.31%113.89%22.83%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$171.13M$37.41M$40.91M$250.01M$80.00M----
Avg Forecast$180.41M$13.62M$46.16M$179.77M$90.30M$68.24M$79.33M$78.19M$110.38M
High Forecast$262.75M$19.84M$70.73M$180.41M$94.99M$110.54M$81.79M$78.19M$202.31M
Low Forecast$98.54M$7.44M$15.86M$179.40M$85.71M$3.07M$76.87M$78.19M$5.62M
Surprise %-5.14%174.70%-11.39%39.07%-11.40%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$36.74M$-66.03M$-46.41M$132.33M$-65.00M----
Avg Forecast$1.01B$-104.45M$-109.02M$132.33M$-38.68M$-103.67M$-61.48M$-62.84M$-30.31M
High Forecast$1.24B$-42.83M$-87.21M$158.80M$-29.86M$-28.35M$-24.69M$-34.32M$7.09M
Low Forecast$786.50M$-166.43M$-130.82M$105.86M$-47.50M$-138.58M$-98.26M$-91.36M$-63.12M
Surprise %-96.38%-36.78%-57.43%-68.05%----

VYGR Forecast FAQ

Is Voyager Therapeutics stock a buy?

Voyager Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Voyager Therapeutics is a favorable investment for most analysts.

What is Voyager Therapeutics's price target?

Voyager Therapeutics's price target, set by 19 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $10 at the low end to $18 at the high end, suggesting a potential 343.04% change from the previous closing price of $3.16.

How does Voyager Therapeutics stock forecast compare to its benchmarks?

Voyager Therapeutics's stock forecast shows a 343.04% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Voyager Therapeutics over the past three months?

  • April 2025: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Voyager Therapeutics’s EPS forecast?

Voyager Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.6, marking a 41.59% increase from the reported $-1.13 in 2024. Estimates for the following years are $-1.34 in 2026, $-1.31 in 2027, and $-0.68 in 2028.

What is Voyager Therapeutics’s revenue forecast?

Voyager Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $68.24M, reflecting a -14.70% decrease from the reported $80M in 2024. The forecast for 2026 is $79.33M, followed by $78.19M for 2027, and $110.38M for 2028.

What is Voyager Therapeutics’s net income forecast?

Voyager Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-104M, representing an 59.48% increase from the reported $-65.002M in 2024. Projections indicate $-61.478M in 2026, $-62.84M in 2027, and $-30.307M in 2028.